LY517717

Anticoagulant drugs comprise a specific subcategory of antithrombotic agents that act to inhibit blood coagulation at various… Expand

After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most… Expand

Following the clinical approval of novel oral anticoagulants as alternatives to the vitamin K antagonists, many additional novel… Expand

In the last 20 years the advent of new technologies, such as high-throughput screening (HTS) and combinatorial chemistry, has… Expand

BACKGROUND LY517717 is an oral direct inhibitor of activated factor X that is currently under clinical development. OBJECTIVES… Expand

Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing… Expand

Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K… Expand

12B75, 274150; Abacavir sulfate/lamivudine, Abatacept, Ad2/HIF-1alpha, Adalimumab, Adefovir, Adefovir dipivoxil, AGN-201904-Z… Expand

 

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data the… Expand